Cohance Lifesciences Limited (BOM:543064)

Market Cap	138.18B -51.1%
Revenue (ttm)	10.79B +2.9%
Net Income	606.40M -78.3%
EPS	2.35 -78.5%
Shares Out	n/a
PE Ratio	227.87
Forward PE	38.29
Dividend	n/a
Ex-Dividend Date	n/a

Volume	211,056
Average Volume	401,747
Open	369.35
Previous Close	369.35
Day's Range	359.00 - 371.55
52-Week Range	267.85 - 1,246.85
Beta	n/a
RSI	59.48
Earnings Date	May 29, 2026

About Cohance Lifesciences

Cohance Lifesciences Limited engages in the contract research, development, and manufacturing of new chemical entity (NCE) based intermediates, active pharmaceutical ingredients (API), specialty chemicals, and formulated drugs in India, the United States, Europe, and internationally. The company offers small molecule APIs, advanced intermediates, and starting materials; antibody drug conjugates; high-purity oligonucleotide building blocks comprising phosphoramidites, nucleosides, pseudouridine, NTPs, CAP reagents, GalNAc conjugates, and fluores...

• Industry: Pharmaceutical Preparations
• Founded: 1989
• Employees: 1,212
• Stock Exchange: Bombay Stock Exchange
• Ticker Symbol: 543064

Financial Performance

In fiscal year 2025, Cohance Lifesciences's revenue was 11.98 billion, an increase of 13.91% compared to the previous year's 10.51 billion. Earnings were 2.68 billion, a decrease of -10.79%.